Evidence map›Paper›PMID 41182377›Full record

ArticleCancer immunology, immunotherapy : CII2025

Advancing CIK cell immunotherapy: highlights from the second international conference on DC-CIK and CAR-CIK approaches.

Amit Sharma, Dario Sangiolo, Antonio Rosato, Jingjing Pu, Jian Hou, Sarah Tettamanti, Marta Serafini, Kevin Aaron Fenix, Martino Introna, Alessandro Rambaldi and 2 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Amit SharmaDepartment of Integrated Oncology, Center for Integrated Oncology (CIO) Bonn, University Hospital Bonn, Bonn, Germany.
Dario SangioloDepartment of Oncology, University of Turin, Turin, Italy.
Antonio RosatoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.
Jingjing PuDepartment of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Jian HouDepartment of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Sarah TettamantiTettamanti Center, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
Marta SerafiniTettamanti Center, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
Kevin Aaron FenixDiscipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
Martino IntronaCenter of Cellular Therapy G. Lanzani, Division of Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy.
Alessandro RambaldiDepartment of Oncology and Hematology, University of Milan, Milan, Italy.
Xiubao RenTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Ingo G H Schmidt-WolfDepartment of Integrated Oncology, Center for Integrated Oncology (CIO) Bonn, University Hospital Bonn, Bonn, Germany. ingo.schmidt-wolf@ukbonn.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On April 7, 2025, the 2nd International CIK Cell Conference was held in Monza, Italy, marking the establishment of the International Society for CIK Cells (ISCC). The conference, kindly supported by Fondazione Tettamanti (Italy), featured cutting-edge advancements in cytokine-induced killer (CIK) cell immunotherapy, used alone and in combination with dendritic cells (DC-CIK) and chimeric antigen receptors (CAR-CIK). The event also provided a valuable opportunity for young investigators to engage in insightful discussions and to network within experts in the field.

Indexed as

Cytokine-Induced Killer CellsDendritic CellsImmunotherapyImmunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenHumansReceptors, Chimeric AntigenCAR-CIKCytokine-induced killer (CIK) cell immunotherapyDC-CIKInternational society for CIK cellsISCC

Identifiers

PMID41182377
PMCPMC12583270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.